Charles River Laboratories International (CRL) EBIT (2009 - 2025)

Charles River Laboratories International's EBIT history runs 17 years deep, the most recent figure standing at -$283.4 million for Q4 2025.

• In Q4 2025, EBIT fell 69.03% year-over-year to -$283.4 million; the TTM figure through Dec 2025 stood at $25.2 million (down 88.93% YoY), while the FY2025 annual figure was $25.2 million, down 88.93% from the prior year.
• EBIT was -$283.4 million for Q4 2025 at Charles River Laboratories International, down from $133.8 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $187.4 million in Q2 2022 to a low of -$283.4 million in Q4 2025.
• Historically, EBIT has averaged $105.5 million across 5 years, with a median of $143.2 million in 2021.
• The sharpest annual moves came in 2021 and 2024: EBIT soared 79.18% in 2021, then tumbled 226.15% in 2024.
• A 5-year view of EBIT shows it stood at $172.8 million in 2021, then slipped by 5.21% to $163.8 million in 2022, then retreated by 18.86% to $132.9 million in 2023, then sank by 226.15% to -$167.7 million in 2024, then tumbled by 69.03% to -$283.4 million in 2025.
• The last three EBIT figures came in at -$283.4 million (Q4 2025), $133.8 million (Q3 2025), and $100.1 million (Q2 2025), per Business Quant data.